NEWTOWN, Pa.--(BUSINESS WIRE)--BioClinica®, Inc. (NASDAQ: BIOC), a global provider of clinical trial management solutions, today announced that members of its team will attend, participate in and speak at several upcoming industry conferences in April, May, and June. BioClinica experts will discuss industry trends and also demonstrate its suite of technologies and solutions. The conferences include:
April 19 – 20, 2012
ShareFEST is the premier Microsoft SharePoint Conference for Life Sciences. The conference attracts hundreds of attendees from pharmaceutical companies, device manufacturers, biotechs, and service providers from around the world. BioClinica is a Gold Sponsor of ShareFEST and will demonstrate its industry-leading eClinical products that are designed to harness the power of SharePoint. Jeremiah Rehm, a BioClinica eClinical Specialist, will present on the topic “Site Monitoring Made Easy.” On April 19 BioClinica and Paragon Solutions will co-sponsor a hospitality suite featuring Philadelphia foods, local beers, and the opportunity for attendees to win an Xbox 360 gaming system.
64th Annual American Academy of Neurology
April 21 – 28, 2012
New Orleans, Louisiana
The American Academy of Neurology Annual Meeting is the biggest neurology event in the world and promises to be a valuable experience with a customizable schedule of education, science, and practice programs. Dr. Chahin Pachai will demonstrate BioClinica’s technology-enhanced imaging core lab expertise and trial management services at the AAN Meeting. Dr. Pachai is the Vice President and Executive Director of BioClinica’s Lyon, France office and is an expert in the field of quantitative MRI, image segmentation and CNS diseases.
Global Clinical Supplies Group
April 22 – 25, 2012
Global Clinical Supplies Group is a forum for open discussion to share knowledge and the industry's best practices for clinical supply and related professionals. The GCSG conference is the most comprehensive conference in the clinical supply chain arena. BioClinica will demonstrate its suite of clinical trial services that maximize efficiency and manageability of the clinical trial process.
DIA Clinical Data Quality Summit
April 24 – 25, 2012
The Drug Information Association’s Clinical Data Quality Summit features a mix of highly interactive plenary and breakout sessions. Participants will troubleshoot, share processes, and exchange ideas with colleagues from various clinical areas while exploring new tools, technologies, and techniques for conducting remote-based and targeted monitoring. Jonathan Andrus, BioClinica’s Vice President of Data Management and Quality, is a member of the program committee and will chair the Study Conduct session with Dr. Sean Kassim from the FDA.
2012 OARSI World Congress on Osteoarthritis
April 26 – 29, 2012
The annual OARSI Congress is a global forum for all people involved in osteoarthritis research and treatment. This meeting features speakers from around the world presenting up-to-date information on a wide range of topics related to joint damage and osteoarthritis. Colin Miller, Ph.D., BioClinica’s Senior Vice President of Medical Affairs, will present a co-authored OARSI oral presentation with Marie-Pierre Hellio Le Graverand-Gastineau, MD, of Pfizer Global Research and Development.
Outsourcing in Clinical Trials Europe
May 8 – 9, 2012
The growing complexity and global nature of modern clinical trials makes the need to outsource greater than ever. Outsourcing in Clinical Trials bring major pharmaceutical and biotech manufacturers together to debate potential solutions to the complex challenges of running global clinical trials. BioClinica will demonstrate their full line of eClinical solutions and Imaging Core Lab Services that are designed to meet the individual needs of today’s complex global studies.
Outsourcing in Clinical Trials Southeast
May 15 – 16, 2012
Durham, North Carolina
The growing complexity and global nature of modern clinical trials makes the need to outsource greater than ever. The Outsourcing in Clinical Trials Southeast conference promises to provide an exclusive hub for stimulating innovative thought and adaptable proactive solutions. The event will tackle major concerns of outsourcing such as vendor selection and management, patient recruitment in the emerging markets, data management, FDA regulations and many more challenges. BioClinica will demonstrate their industry-leading eClinical solutions and Imaging Core Lab services.
American Society of Clinical Oncology Annual Meeting
June 1 – 5, 2012
Booth # 16105
Bringing together more than 30,000 oncology professionals from a broad range of specialties, the 2012 ASCO Annual Meeting will feature cutting-edge scientific presentations and comprehensive educational content. More than 5,000 abstracts are accepted each year, showcasing the latest breakthroughs in the progress against cancer with important and sometimes immediate implications for patient care and practice. Dr. Andy Dzik-Jurasz, BioClinica’s Senior Medical Director, will attend ASCO to demonstrate BioClinica’s expertise in oncology medical imaging management. In addition, Mirada Medical and BioClinica will jointly demonstrate the expanded molecular imaging capabilities that BioClinica can provide through their recently announced partnership. BioClinica will integrate Mirada’s XD3 software solution into its imaging core lab technology to further enhance its PET capabilities and expertise for molecular imaging trials.
Clinical Trial Oversight Summit
June 4 – 7, 2012
The inaugural Clinical Trial Oversight Summit will include presentations from experts, case studies, interactive breakout discussion groups, workshops, and networking opportunities. Topics will include risk-based approaches to clinical trial management, implementing quality systems-based approaches to GCP compliance, ensuring reliable study data, responding to the evolving regulatory landscape, and preparing sites and clinical research partners for inspection-readiness. Jonathan Andrus, Vice President of Data Management and Quality, will present the topic “Partnering for Clinical Trial Success: Johnson and Johnson Vision Care (Vistakon) and BioClinica.”
Annual EULAR 2012 Congress
June 6 – 9, 2012
The aim of the European League Against Rheumatism annual congress is to provide a forum of the highest standard for scientific, educational, and social exchange between professionals involved in rheumatology, liaising with patient organizations, in order to achieve progress in the clinical care of patients with rheumatic diseases. BioClinica will co-author two poster presentations with Dr. María Victoria Navarro Compán of Leiden University Medical Center titled “Calculation of the Smallest Detectable Change (SDC) of Radiographic Progression in Clinical Trials with Multiple Time Points: The Mean SDC is a Valid Approximation of the Overall SDC and Prediction of Rate of Adjudication of Radiological Progression in Rheumatoid Arthritis (RA) Randomized Controlled Trials (RCTS) in Early and Established Disease.”
Drug Information Association 48th Annual
June 24 – 28, 2012
The DIA annual meeting is the pharmaceutical industry’s premier event. More than 7,500 professionals involved in the discovery, development, and life cycle management of pharmaceuticals, biotechnology, medical devices, and related products will come together to foster innovation and facilitate health and well-being worldwide. BioClinica will demonstrate its innovative eClinical solutions and leading Imaging Core Lab services. Jonathan Andrus, Vice President of Data Management and Quality and chair of the DIA eClinical SIAC showcase session, will speak on June 26th in the 3:30pm session on “Controversial Guidance, eSource and Standards: How Does It All Fit Together in an eClinical World?”
About BioClinica, Inc.
BioClinica, Inc. is a leading global provider of integrated, technology-enhanced clinical trial management solutions. BioClinica supports pharmaceutical and medical device innovation with imaging core lab, internet image transport, electronic data capture, interactive voice and web response, clinical trial management and clinical supply chain design and optimization solutions. BioClinica solutions maximize efficiency and manageability throughout all phases of the clinical trial process. With over 20 years of experience and more than 2,000 successful trials to date, BioClinica has supported the clinical development of many new medicines from early phase trials through final approval. BioClinica operates state-of-the-art, regulatory-body-compliant imaging core labs on two continents, and supports worldwide eClinical and data management services from offices in the United States, Europe and Asia. For more information, please visit www.bioclinica.com
Certain matters discussed in this press release are “forward-looking statements” intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company’s statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the consummation and the successful integration of current and proposed acquisitions, the timing of projects due to the variability in size, scope and duration of projects, estimates and guidance made by management with respect to the Company’s financial results, backlog, critical accounting policies, regulatory delays, clinical study results which lead to reductions or cancellations of projects, and other factors, including general economic conditions and regulatory developments, not within the Company’s control. The factors discussed herein and expressed from time to time in the Company’s filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance. You should review the Company’s filings, especially risk factors contained in the Form 10-K and the recent Form 10-Q.